Campylobacter species and Guillain-Barre syndrome

被引:418
作者
Nachamkin, I
Allos, BM
Ho, T
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA
[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
关键词
D O I
10.1128/CMR.11.3.555
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Since the eradication of polio in most parts of the world, Guillain-Barre syndrome (GBS) has become the most common cause of acute flaccid paralysis. GBS is an autoimmune disorder of the peripheral nervous system characterized by weakness usually symmetrical, evolving over a period of several days or more. Since laboratories began to isolate Campylobacter species from stool specimens some 20 years ago, there have been many reports of GBS following Campylobacter infection. Only during the past few years has strong evidence supporting this association developed. Campylobacter infection is now known as the single most identifiable antecedent infection associated with the development of GBS. Campylobacter is thought to cause this autoimmune disease through a mechanism called molecular mimicry, whereby Campylobacter contains ganglioside-like epitopes in the lipopolysaccharide moiety that elicit autoantibodies reacting with peripheral nerve targets. Campylobacter is associated with several pathologic forms of GBS, including the demyelinating (acute inflammatory demyelinating polyneuropathy) and axonal (acute motel axonal neuropathy) for-ms. Differ ent strains Of Campylobacter as well as host factors likely play an important role in determining who develops GBS as well as the nerve targets for the host immune attack of peripheral nerves. The purpose of this; review is to summarize our current knowledge about the clinical, epidemiological, pathogenetic and laboratory aspects of campylobacter-associated GBS.
引用
收藏
页码:555 / +
页数:14
相关论文
共 183 条
[21]   GUILLAIN-BARRE-SYNDROME AND ITS RELATIONSHIP TO SWINE INFLUENZA VACCINATION IN MICHIGAN, 1976-1977 [J].
BREMAN, JG ;
HAYNER, NS .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1984, 119 (06) :880-889
[22]   PROGNOSIS IN GUILLAIN-BARRE-SYNDROME [J].
BRISCOE, DM ;
MCMENAMIN, JB ;
ODONOHOE, NV .
ARCHIVES OF DISEASE IN CHILDHOOD, 1987, 62 (07) :733-735
[23]   Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice [J].
Buchwald, B ;
Weishaupt, A ;
Toyka, KV ;
Dudel, J .
NEUROSCIENCE LETTERS, 1995, 201 (02) :163-166
[24]  
CALVA JJ, 1988, LANCET, V1, P503
[25]   THE AETIOLOGY OF POLYNEURITIS [J].
CAMPBELL, AMG .
PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1958, 51 (03) :157-159
[26]   HLA AND ANTI-GQ1B IGG ANTIBODY IN MILLER-FISHER SYNDROME AND GUILLAIN-BARRE-SYNDROME [J].
CHIBA, A ;
KUSUNOKI, S ;
KUWATA, S ;
JUJI, T ;
SHIBATA, Y ;
KANAZAWA, I .
JOURNAL OF NEUROIMMUNOLOGY, 1995, 61 (01) :85-88
[27]   SERUM ANTI-GQ(1B) IGG ANTIBODY IS ASSOCIATED WITH OPHTHALMOPLEGIA IN MILLER FISHER SYNDROME AND GUILLAIN-BARRE-SYNDROME - CLINICAL AND IMMUNOHISTOCHEMICAL STUDIES [J].
CHIBA, A ;
KUSUNOKI, S ;
OBATA, H ;
MACHINAMI, R ;
KANAZAWA, I .
NEUROLOGY, 1993, 43 (10) :1911-1917
[28]   SERUM IGG ANTIBODY TO GANGLIOSIDE GQ1B IS A POSSIBLE MARKER OF MILLER FISHER SYNDROME [J].
CHIBA, A ;
KUSUNOKI, S ;
SHIMIZU, T ;
KANAZAWA, I .
ANNALS OF NEUROLOGY, 1992, 31 (06) :677-679
[29]  
COE C J, 1989, Yonsei Medical Journal, V30, P81
[30]   PROGNOSIS IN SEVERE GUILLAIN-BARRE-SYNDROME [J].
COLE, GF ;
MATTHEW, DJ .
ARCHIVES OF DISEASE IN CHILDHOOD, 1987, 62 (03) :288-291